Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in myasthenia gravis.

Emma Ciafaloni1, Donald B Sanders

  • 1Duke University Medical Center, 932 Morreene Road, Room 230, Durham, NC 27705, USA. ciafa001@mc.duke.edu

Current Neurology and Neuroscience Reports
|March 20, 2002
PubMed
Summary

Recent advances in myasthenia gravis (MG) diagnosis and treatment are reviewed. New antibodies, immunosuppressants like mycophenolate mofetil, and potential vaccines offer improved management strategies for this autoimmune disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Validation of a Novel, Disease-Specific, Caregiver-Reported Outcome Measure: The Duchenne Muscular Dystrophy Caregiver Reported-Health Index (DMDCR-HI).

Muscle & nerve·2026
Same author

Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross-Trial Comparison.

Muscle & nerve·2026
Same author

Population-Based Investigation of DMD Genotype and Neurodevelopmental Concerns in Duchenne Muscular Dystrophy.

Neuropediatrics·2026
Same author

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Muscle & nerve·2026
Same author

Prenatal Diagnosis of Spinal Muscular Atrophy Facilitates Ultrarapid Treatment After Birth.

Pediatric neurology·2026
Same author

Immunotherapies in autoimmune neuromuscular junction disorders: Acute and chronic management.

Handbook of clinical neurology·2026

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Acquired myasthenia gravis (MG) diagnosis and treatment have seen recent advancements.
  • There is a growing need for standardized reporting methods in MG treatment trials.
  • Developing better disease classifications and outcome measures is crucial for advancing MG research.

Purpose of the Study:

  • To review recent progress in the diagnosis and treatment of acquired myasthenia gravis.
  • To highlight emerging diagnostic markers and therapeutic options.
  • To discuss the potential for novel interventions, including vaccines.

Main Methods:

  • Systematic review of the existing literature on myasthenia gravis.
  • Analysis of newly discovered antibodies in seronegative MG patients.
  • Evaluation of mycophenolate mofetil as a treatment option.
  • Review of research supporting the development of an MG vaccine.

Main Results:

  • Discovery of new antibodies in seronegative MG patients suggests distinct disease forms.
  • Mycophenolate mofetil emerges as a potentially safe and effective immunosuppressant for MG.
  • Research indicates the feasibility of developing a human-trial-ready vaccine against MG.

Conclusions:

  • Advances in diagnostics and therapeutics are improving acquired myasthenia gravis management.
  • Novel antibodies may define new subtypes of MG.
  • Mycophenolate mofetil and potential vaccines represent promising future directions for MG treatment.

Related Experiment Videos